We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Feature

'Revolving Door' At DEA Faces Scrutiny In Opioid MDL

Law360 (March 1, 2018, 11:28 PM EST) -- The U.S. Drug Enforcement Administration’s resistance to divulging information about opioid sales as part of multidistrict litigation is generating fresh scrutiny of its “revolving door” relationship with drug companies and law firms.

The DEA’s opposition has spilled into public view as plaintiffs lawyers in the opioid MDL seek access to a massive government database with information from drug companies about painkiller sales. Citing trade secrets and other issues, the DEA has so far been willing to divulge only two years of data, but U.S. District Judge...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.